Find News

Filter articles

Applied Filters

Showing 71 to 80 of 832 results

City of Baltimore accuses Janssen of delaying generics


Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is being sued for “unlawfully” delaying generic competition to Zytiga, its branded cancer medication.

Federal Circuit invalidates Nuvo’s Vimovo patents


The US Court of Appeals for the Federal Circuit has delivered a blow to Nuvo Pharmaceuticals by reversing a decision which had upheld the validity of the Canadian company’s pain relief drug Vimovo.

EU adopts SPC manufacturing waiver


The European Union has adopted the proposed supplementary protection certificate manufacturing waiver, despite criticism from parts of the pharmaceutical industry.

Federal Circuit rules against J&J in Zytiga dispute


The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.

Clean sweep for AbbVie in Humira litigation


Boehringer Ingelheim has become the latest biosimilar maker to resolve litigation over AbbVie’s arthritis treatment Humira.

44 states accuse big pharma of price fixing generics market


44 US states have filed a joint complaint against 20 drug companies, alleging they engaged in illegal conspiracies to “manipulate prices, reduce competition” and restrain trade for more than 100 generic drugs.

E+F patent attorney elevated to partner


Elkington + Fife has unveiled Mark Scott as a new partner in the UK firm’s patent practice.

Federal Circuit backs Sandoz in Amgen biosimilar suit


The US Court of Appeals for the Federal Circuit yesterday, May 8, rejected an appeal from Amgen in patent litigation relating to two Sandoz biosimilars.

Generic of Gilead’s HIV pre-exposure drug coming to market in 2020


A generic version of Gilead’s Truvada will hit the market in 2020, a year earlier than expected.

Eli Lilly secures victory before Federal Circuit


The US Court of Appeals for the Federal Circuit affirmed a series of Patent Trial and Appeal Board inter partes reviews, which upheld a patent owned by Eli Lilly late last week.

Showing 71 to 80 of 832 results